A long answer on evaluation of patients with CVS disease for anasesthesia mentioning MACE, NICE guidelines, AHA guidelines, RCRI, CHADVsC score, and JNC guidelines for HTN .And any other relevant guidelines

Reading File

Finding Sources

Searching the Web

preoperative cardiovascular evaluation anaesthesia MACE RCRI AHA NICE guidelines 2024

Reading File

Finding Sources

Reading Web Page

2024 ACC AHA perioperative cardiovascular guidelines MACE RCRI functional capacity stepwise algorithm

Finding Sources

Searching the Web

NICE guideline NG45 preoperative tests routine 2016 updated cardiovascular risk assessment

Reading File

Loading Image

Searching the Web

JNC 8 hypertension guidelines perioperative management blood pressure threshold anaesthesia 2024

I now have comprehensive data from textbooks, the 2024 ACC/AHA guidelines, NICE NG45, JNC 8, and the ESC 2022 guidelines. Let me now compose the full detailed answer.

Preoperative Cardiovascular Evaluation for Anaesthesia: A Comprehensive Review

1. Principles and Goals

The concept of "cardiac clearance" is a misnomer and should be abandoned. The real goal of preoperative cardiovascular evaluation is cardiac risk stratification - identifying risks, optimising the patient medically, selecting appropriate monitoring strategies, and in rare cases, deferring surgery for revascularisation. Prophylactic revascularisation to reduce perioperative risk is only indicated where it would be warranted anyway in the non-surgical setting (i.e., acute coronary syndrome or >50% left main coronary stenosis).

A multidisciplinary team approach - involving the surgeon, anaesthesiologist, cardiologist, and the patient - is central to all major guidelines.

2. Defining MACE

Major Adverse Cardiac Events (MACE) refers to a composite endpoint of perioperative cardiac death, non-fatal myocardial infarction, and non-fatal cardiac arrest. The 2024 AHA/ACC guidelines frame the entire preoperative evaluation around estimating the risk of MACE. A risk of <1% is considered low risk and generally permits proceeding directly to surgery, whereas ≥1% is elevated risk and triggers further assessment.

The spectrum of myocardial damage in the perioperative period ranges from subclinical troponin elevation (myocardial injury after noncardiac surgery - MINS) through to overt MI and sudden cardiac death. Patients with a history of cardiovascular disease or known cardiac risk factors undergoing major surgery are specifically at risk of MACE. The highest risk of a further event is within the first month post-surgery.

3. The ACC/AHA Stepwise Algorithm (2024 Guidelines)

The 2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery (published September 2024, superseding the 2014 guidelines) provides a revised stepwise algorithm. The 2014 framework has been updated with new evidence, new timing definitions, and an expanded set of risk modifiers.

Stepwise ACC/AHA perioperative cardiac assessment algorithm for CAD

Stepwise approach to perioperative cardiac assessment - Morgan & Mikhail's Clinical Anesthesiology

Step 1: Determine Urgency of Surgery

Revised 2024 Definitions:

Category	Timeframe
Emergency	< 2 hours (previously < 6 hours)
Urgent	2-24 hours (previously 6-24 hours)
Time-sensitive	Up to 3 months (previously 1-6 weeks)
Elective	Deferrable beyond 3 months

For emergency surgery: proceed immediately. Identify clinical risk factors that influence perioperative management and use them to guide monitoring and treatment intraoperatively.

Step 2: Screen for Acute Coronary Syndrome (ACS)

If the patient has active cardiac conditions, elective surgery must be postponed:

Acute coronary syndrome (STEMI, NSTEMI, unstable angina)
Decompensated heart failure
Significant arrhythmias (high-degree AV block, symptomatic ventricular arrhythmias, SVT with uncontrolled rate)
Severe valvular heart disease (new category in 2024)

These patients must be referred for cardiology evaluation and treated according to guideline-directed medical therapy (GDMT).

Timing after PCI/revascularisation (2024 recommendations):

ACS/MI within 60 days: delay surgery
Bare-metal stent (BMS): delay at least 30 days
Drug-eluting stent (DES): optimally delay 6 months; minimum 3 months if time-sensitive; avoid within 1 month
High-risk PCI features: consider delay up to 12 months

Step 3: Estimate Perioperative Risk of MACE

Using the combined clinical/surgical risk, estimate MACE probability using validated tools (see Section 4 on RCRI and MICA). The 2024 guidelines give a Class IIa recommendation to use a validated risk prediction tool.

Low risk (<1% MACE): Proceed to surgery - no further testing needed (Class III: No Benefit)
Elevated risk (≥1% MACE): Assess functional capacity

Step 4: Assess Functional Capacity

Metabolic Equivalents (METs) are the standard measure:

METs	Capacity
> 10	Excellent
7-10	Good
4-6	Moderate
< 4	Poor

1 MET = resting/basal O₂ consumption of a 70-kg, 40-year-old man (~3.5 mL/kg/min)

Representative activities:

1 MET: Self-care, eating, dressing
4 METs: Walking on level ground at 4 mph, climbing one flight of stairs
7 METs: Playing doubles tennis
10 METs: Strenuous sports (swimming, singles tennis)

The 2024 guidelines add a Class IIa recommendation to use the Duke Activity Status Index (DASI) as a structured tool for functional capacity assessment - a DASI score ≤34 is associated with increased odds of 30-day death or myocardial ischaemia.

METs ≥4: Proceed to surgery without further testing (Class IIa for excellent; Class IIb for moderate-good)
METs <4 or unknown: Ask: "Will further testing change management or perioperative care?"

Step 5: Further Testing (for Poor/Unknown Functional Capacity)

If further testing will change management:

Pharmacologic stress testing (Class IIa) - preferred when patient cannot exercise adequately
If normal: Proceed to surgery with GDMT
If abnormal: Coronary revascularisation according to existing guidelines (Class I)

If further testing will NOT change management - proceed to surgery with GDMT or consider alternative strategies (noninvasive treatment, palliation).

4. Risk Stratification Scores

4.1 Revised Cardiac Risk Index (RCRI)

The RCRI, developed by Lee et al. (1999) and validated in multiple large studies, is the most widely used and guideline-endorsed preoperative cardiac risk tool. It is endorsed by the ACC/AHA, ESC, ESA, and AHA guidelines.

Variable	Points
High-risk surgery (intraperitoneal, intrathoracic, or suprainguinal vascular)	1
History of ischaemic heart disease	1
History of congestive heart failure	1
History of cerebrovascular disease (stroke or TIA)	1
Insulin therapy for diabetes mellitus	1
Preoperative serum creatinine >2.0 mg/dL (>177 µmol/L)	1

Risk Classification:

RCRI Score	Risk Class	Estimated Complication Risk
0	I (Very Low)	0.4%
1	II (Low)	0.9%
2	III (Moderate)	7.0%
≥3	IV (High)	11.0%

The RCRI's main advantages are its ease of use and objective criteria. Its limitations include moderate discriminatory power between low and high risk and the fact that it was not designed for specific high-risk populations.

4.2 Gupta MICA Calculator (ACS NSQIP)

The Myocardial Infarction or Cardiac Arrest (MICA) calculator is derived from the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) dataset. It is endorsed as an alternative/supplement to RCRI by the ACC/AHA.

Variables included: Type of surgery, functional status, serum creatinine, ASA physical status class, and age.

The 2024 ACC/AHA guidelines recommend using RCRI, MICA, or the ACS Surgical Risk Calculator (ACS-SRC) for MACE estimation.

4.3 AUB-HAS2 Cardiovascular Risk Index

A newer score from the American University of Beirut, validated using ACS NSQIP data. Predictors include:

History of heart disease
Symptoms of heart disease (angina or dyspnoea)
Age ≥75 years
Anaemia (Hb <12 g/dL)
Vascular or emergency surgery

4.4 CHA₂DS₂-VASc Score

Although primarily used to estimate thromboembolic risk in atrial fibrillation (AF) to guide anticoagulation therapy, the CHA₂DS₂-VASc score is relevant to perioperative cardiovascular evaluation because:

AF management perioperatively - patients with AF scheduled for surgery require risk-stratified decisions about bridging anticoagulation and rate/rhythm control. A higher CHA₂DS₂-VASc score indicates greater stroke risk during the perioperative anticoagulation interruption window.
Risk modifier - AF itself is a marker of underlying structural heart disease and increases operative risk.
Postoperative AF (POAF) - the 2024 ACC/AHA guidelines explicitly address POAF management; the CHA₂DS₂-VASc is used to guide anticoagulation decisions post-POAF.

Variable	Points
Congestive heart failure	1
Hypertension	1
Age ≥75 years	2
Diabetes mellitus	1
Stroke/TIA/thromboembolism history	2
Vascular disease (prior MI, PAD, aortic plaque)	1
Age 65-74 years	1
Sex category (female)	1

Score interpretation: Score ≥2 (males) or ≥3 (females) - anticoagulation recommended. In the perioperative setting, if anticoagulation must be withheld, bridging therapy decisions hinge on this score.

5. Surgical Risk Classification

Surgery itself contributes to perioperative cardiac risk independently of patient factors. The ESC 2022 and ACC/AHA guidelines stratify surgical risk as:

Risk Level	30-Day MACE	Examples
Low	<1%	Endoscopic, superficial, breast, cataract, minor orthopaedic, ambulatory
Intermediate	1-5%	Intraperitoneal, intrathoracic, orthopaedic spine, prostate
High	>5%	Aortic/major vascular, peripheral vascular

6. Preoperative Diagnostic Testing

The decision to order tests must be guided by whether the result will change management - not obtained routinely.

ECG

Indicated for patients with known CAD, arrhythmia, peripheral artery disease, or cerebrovascular disease
May be considered in asymptomatic patients before intermediate- or high-risk procedures
Not required before low-risk procedures

Echocardiography

Reasonable for dyspnoea of unknown origin or progressive heart failure
Should be considered for known LV dysfunction if no assessment within 1 year or if functional status has declined
2024 NICE NG45 added resting echocardiography to the guideline framework

Stress Testing (Exercise/Pharmacologic)

Reserved for elevated-risk patients with poor/unknown functional capacity where results will change management
Dobutamine stress echocardiography or myocardial perfusion imaging are the preferred modalities when the patient cannot exercise
Exercise ECG is less sensitive for detecting ischaemia in multivessel disease

Biomarkers

BNP/NT-proBNP: The 2024 guidelines include preoperative natriuretic peptides as a Class IIa recommendation for risk stratification in elevated-risk patients
High-sensitivity troponin: Useful for postoperative MINS surveillance
NT-proBNP values above the upper limit of normal (adjusted for age) indicate higher perioperative risk

7. NICE Guidelines (NG45, 2016, updated 2024)

NICE Guideline NG45: Routine Preoperative Tests for Elective Surgery (published April 2016, last updated 2024) covers adults aged >16 years undergoing elective surgery. It does NOT cover cardiothoracic procedures, neurosurgery, or pregnant patients.

The core philosophy is reducing unnecessary testing while ensuring appropriate testing for patients with comorbidities (cardiovascular disease, renal disease, respiratory disease, diabetes, and obesity). Tests are recommended according to:

Grade of surgery: Minor / Intermediate / Major or Complex
Patient comorbidities: ASA grade essentially maps onto this

Key cardiovascular-relevant NICE NG45 recommendations:

Test	When indicated (cardiovascular)
12-lead ECG	Cardiovascular disease (all grades); consider in ASA 3+ for intermediate/major surgery
Resting echocardiogram	Suspected heart failure, known LV dysfunction, significant murmur before major surgery
Full blood count	Major surgery; cardiovascular disease with major/complex surgery
Renal function (U&E)	Cardiovascular disease patients; those on diuretics, ACE inhibitors, ARBs; major surgery
HbA1c	Diabetic patients (added to NG45 in 2016 update)

NG45 explicitly states that routine testing without clinical indication (e.g., ECG in a healthy young person having minor surgery) should not be performed, as false positives lead to unnecessary investigations, anxiety, and delays.

8. Hypertension and Anaesthesia: JNC Guidelines

JNC 7 Classification (2003)

Category	Systolic (mmHg)	Diastolic (mmHg)
Normal	<120	<80
Prehypertension	120-139	80-89
Stage 1 HTN	140-159	90-99
Stage 2 HTN	≥160	≥100
Hypertensive crisis	≥180	≥120

JNC 8 (2014) - Key Changes from JNC 7

JNC 8 took a more practical, evidence-based approach focused on treatment initiation thresholds and goals rather than staging:

Population	Treatment Threshold	BP Goal
Age ≥60 years	BP ≥150/90 mmHg	<150/90 mmHg
Age 18-59 years (no DM/CKD)	BP ≥140/90 mmHg	<140/90 mmHg
Diabetes mellitus (any age)	BP ≥140/90 mmHg	<140/90 mmHg
CKD (any age)	BP ≥140/90 mmHg	<140/90 mmHg

Drug choices per JNC 8:

Non-Black patients: thiazide, ACE inhibitor/ARB, or calcium channel blocker (CCB)
Black patients: thiazide or CCB as first-line
CKD patients: ACE inhibitor or ARB mandatory

Note: The ACC/AHA 2017 hypertension guidelines (replacing JNC 8) lowered the definition of hypertension to ≥130/80 mmHg and defined Stage 1 HTN as 130-139/80-89 and Stage 2 as ≥140/90. This is the currently operational standard in the USA, though JNC 8 threshold remains in many perioperative discussions.

Perioperative Hypertension Management

Should surgery be cancelled for hypertension?

The 2014 ACC/AHA perioperative guidelines stated that Stage 1 and Stage 2 hypertension (SBP <180 mmHg and DBP <110 mmHg) is not an independent risk factor for perioperative cardiac events. However, Stage 3 hypertension (SBP ≥180 mmHg or DBP ≥110 mmHg) is generally regarded as a threshold warranting postponement of elective surgery.

The Association of Anaesthetists (UK) guideline targets SBP <160 mmHg and DBP <100 mmHg before elective surgery, with optimisation in primary care before referral.

Clinical rationale for postponing high-stage HTN:

Hypertensive patients show exaggerated haemodynamic lability under anaesthesia
Abrupt disruption of high peripheral resistance by induction agents causes severe hypotension
Risk of myocardial ischaemia, stroke, and acute kidney injury

Perioperative antihypertensive drug management:

Drug Class	Perioperative Recommendation
Beta-blockers	Continue perioperatively (do NOT abruptly stop - rebound hypertension/tachycardia)
ACE inhibitors/ARBs	Continue or withhold morning dose (risk of intraoperative hypotension; surgeon/anaesthetist discretion)
Calcium channel blockers	Continue
Diuretics	Withhold morning dose (hypokalaemia, hypovolaemia risk)
Alpha-2 agonists (clonidine)	Continue (abrupt withdrawal causes rebound hypertension)
Renin inhibitors	Continue

The 2024 ACC/AHA guidelines emphasise caution when continuing antihypertensives in patients with low/low-normal perioperative BPs, those aged ≥65 years, and patients at high risk for perioperative hypotension.

Intraoperative BP targets: Harm from hypotension begins accruing below:

Mean arterial pressure (MAP) <65 mmHg
Systolic BP <90-100 mmHg

9. ESC 2022 Guidelines on Cardiovascular Assessment for Non-cardiac Surgery

The 2022 ESC Guidelines on Cardiovascular Assessment and Management of Patients Undergoing Non-Cardiac Surgery provide a European counterpart to the ACC/AHA guidelines. Key additions include:

Specific recommendations on frailty assessment as a risk modifier
Lee RCRI as the primary risk tool, supplemented by NSQIP calculators
NT-proBNP/BNP integrated into the risk stratification pathway for all elevated-risk patients
Endorsement of high-sensitivity troponin surveillance postoperatively
Specific guidance on chronic coronary syndrome (CCS) vs. ACS distinction
Pulmonary hypertension listed as a major cardiac risk condition
Dedicated sections on specific diseases (HF, valvular disease, arrhythmias, cardiomyopathies, congenital heart disease)

10. Heart Failure in Preoperative Assessment

Heart failure (HF) is the strongest individual predictor of perioperative MACE among the RCRI components. Key considerations:

Decompensated HF - absolute contraindication to elective surgery; must be optimised with diuresis, ACE inhibitor/ARB, beta-blockers, and aldosterone antagonists
Stable, compensated HF - quantify LV function (echocardiography), optimise GDMT
EF ≥50% (HFpEF) - often underappreciated risk; diastolic dysfunction leads to poor tolerance of fluid shifts
EF <40% (HFrEF) - higher risk; BNP/NT-proBNP useful for baseline and risk stratification
BNP thresholds (2024 ACC/AHA): Elevated BNP associated with significantly increased perioperative risk; NT-proBNP >300 pg/mL (age-adjusted upper limit) signals elevated risk

11. Valvular Heart Disease

Condition	Perioperative Implications
Severe aortic stenosis (AS)	Highest risk; AVR or TAVR should be considered before elective major surgery; haemodynamic maintenance critical (sinus rhythm, preload, afterload)
Mitral stenosis	High risk with tachycardia (reduces diastolic filling time); rate control essential
Severe AR/MR	Usually tolerated better; afterload reduction helpful
Prosthetic valves	Anticoagulation management (bridging); endocarditis prophylaxis

12. Coronary Artery Disease - Specific Considerations

Stable, known CAD with coronary evaluation (stress test/catheter) in the past year and no change in symptoms - proceed to surgery
CABG >5 years ago or prior PCI with restenosis symptoms - requires reassessment
Perioperative beta-blocker therapy: should be continued in patients already on them; initiating new beta-blockade immediately before surgery is not recommended (increased risk of stroke and death per the POISE trial)

13. Arrhythmias

Atrial fibrillation (AF): Most common perioperative arrhythmia. Control rate (target HR <100 bpm) before elective surgery. Anticoagulation management depends on CHA₂DS₂-VASc score and bleeding risk (HAS-BLED score).
Ventricular arrhythmias: Sustained VT requires investigation and treatment before elective surgery
Cardiac implantable electronic devices (CIEDs): Pacemakers and ICDs require specific perioperative management - electrosurgical interference, reprogramming, and post-procedure device interrogation

14. Frailty

The 2024 ACC/AHA guidelines newly incorporate frailty as a risk modifier. Frailty is an independent predictor of adverse perioperative outcomes beyond what is captured by traditional cardiac risk indices. Tools include:

Clinical Frailty Scale (CFS)
Fried Frailty Phenotype
FRAIL questionnaire

Frail patients have higher rates of MACE, prolonged hospitalisation, and loss of independence post-surgery.

15. Summary Algorithm (Practical Approach)

Patient scheduled for non-cardiac surgery
         │
         ▼
    Emergency? ──YES──► Proceed; manage risk factors intraoperatively
         │ NO
         ▼
Active cardiac conditions (ACS, decompensated HF,
severe arrhythmia, severe VHD)?
    YES──► Postpone; treat per GDMT
         │ NO
         ▼
Estimate MACE risk (RCRI/MICA/ACS-SRC)
+ Surgery risk category (low/intermediate/high)
         │
    MACE <1%──► Proceed (no further testing)
         │
    MACE ≥1%──► Assess functional capacity (METs/DASI)
                     │
              METs ≥4──► Proceed to surgery
                     │
              METs <4/unknown──► Will testing change management?
                                       YES──► Pharmacologic stress test
                                       NO──► Proceed with GDMT/palliation

16. Preoperative Laboratory Testing Summary

Investigation	Indication
12-lead ECG	Known CVD, arrhythmia, PAD, cerebrovascular disease; age >65 with major surgery
Echocardiogram	Dyspnoea of unknown cause; known LV dysfunction (if not assessed within 1 year); severe valvular disease
Stress test	Poor functional capacity (<4 METs); elevated MACE risk; result will change management
BNP/NT-proBNP	Elevated-risk patients; HF patients
FBC	Major surgery; age ≥65; anticipated significant blood loss
Renal function	CVD patients; diuretics/ACEi/ARB use; major surgery
Electrolytes	Age ≥65 with major surgery; HTN, DM, CVD on relevant medications
HbA1c	Diabetics undergoing vascular or orthopaedic surgery
Coagulation	Anticoagulant use; known coagulopathy; major haemorrhage-risk surgery

Key Guideline References

Guideline	Focus
2024 AHA/ACC Perioperative Cardiovascular Management for Noncardiac Surgery	Comprehensive US guideline; stepwise algorithm; RCRI, MICA, DASI, frailty
2022 ESC Guidelines on Cardiovascular Assessment for Non-Cardiac Surgery	European guideline; NT-proBNP integral; frailty; chronic vs. acute coronary states
NICE NG45 (2016, updated 2024)	UK: Routine preoperative tests; comorbidity-based matrix; reduces over-testing
JNC 8 (2014)	Hypertension management; treatment thresholds; BP goals by patient population
ACC/AHA 2017 HTN Guidelines	Redefined HTN ≥130/80; currently operational US standard
RCRI - Lee et al. (1999)	Six-factor validated cardiac risk index for noncardiac surgery
Association of Anaesthetists UK	BP thresholds (<160/100 mmHg) before elective surgery

A note on currency: The 2024 ACC/AHA guideline is the most up-to-date major international perioperative cardiovascular guideline as of June 2026. It supersedes the 2014 ACC/AHA guideline and updates definitions of surgical urgency, introduces DASI and frailty assessment, reinforces a conservative approach to prophylactic revascularisation, and expands guidance on postoperative care including POAF and MINS.

This is a shared conversation. Sign in to Orris to start your own chat.